We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
Dedicated to our clients' success
Services
Intellectual Property
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Meet our team
Our knowledge, expertise & publications
View all
Events
Deals & Cases
Careers
22 May 2017
Symetis has been acquired by Boston Scientific (NYSE:BSX) for $435 million in an all cash, up-front payment. Symetis is a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions. Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted.
Symetis is advised by VISCHER AG led by Dr. Matthias Staehelin (Partner, Corporate) with Angelo Imperiale (Associate, Corporate), Sebastian Flückiger (Associate, Corporate), Nadia Tarolli (Partner, Tax), Adrian Briner (Associate, Tax) and Klaus Neff (Partner, Regulatory). VISCHER AG also acts as Shareholder Representative.
Categories: Corporate and commercial, Antitrust and Competition, Life Sciences, Pharma, Biotech, Mergers & Acquisitions, Deals & Cases
Attorney at Law and Civil Law Notary (BS/BL)
Attorney at Law, Swiss Certified Tax Expert (2008)
Swiss Certified Public Accountant, Swiss Certified Tax Expert
Attorney at Law
Swiss dental startup Odne (former Lumendo) has raised USD 5.5m to fund the upcoming US market launch...
Artiria Medical SA, a Swiss neurovascular MedTech company developing next-generation...
GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional...